Sign Up
Stories
CASGEVY™ Gene-Edited Therapy Approval in Sight
Share
Europe Approves CRISPR Gene-Edited Thera...
Advancements in Cell Therapies and Sickl...
Advancements in Cell Therapies and Sickl...
Advancements in Sickle Cell Disease Trea...
Overview
API
Vertex Pharmaceuticals receives positive opinions from the European Medicines Agency for CASGEVY™, a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia. Approval decision expected in Q1 2024, with concerns raised over high cost.
Ask a question
How might the approval of CASGEVY™ impact the treatment options for patients with sickle cell disease and transfusion-dependent beta thalassemia in Europe?
In what ways could the approval of CASGEVY™ influence the landscape of gene-edited therapies for other diseases?
What measures can be taken to address the concerns raised over the high cost of CASGEVY™?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage